Alluvi, known as BI 4744, presents a promising advance in weight control therapy. This dual agonist targeting both GLP-1 and GIP targets demonstrates compelling effectiveness in research studies, possibly exceeding https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/